Avid Bioservices Inc (CDMO)

[InternetForumUser]

OMG.. Please..... I already knew about the Trial results and even looked it up again to verify the timline before I responded to your initial post. The results were published over 2 YEARS AGO..

Results from 13 evaluable patients showed that 11 patients (85%) achieved an objective response, including two patients (15%) that achieved a complete response (CR), 9 patients with partial responses (PR) and 2 patients with progressive disease (PD). Median PFS for the combination of bavituximab with weekly paclitaxel was 7.3 months. In addition, the combination of bavituximab and paclitaxel was safe and well-tolerated with the majority of grade 1 or 2 adverse events being paclitaxel related. Approximately half of these patients were classified as "triple negative," a traditionally difficult-to-treat patient population. In addition, treatment with bavituximab reduced circulating PS-expressing microparticles (exosomes) which are immunosuppressive.

http://ir.peregrineinc.com/releasedetail.cfm?releaseid=904275